Background: Cardiac fibrosis is a component of all chronic heart diseases. JAZF1 regulates metabolism through various mechanisms; however, its role in cardiac fibrosis remains unclear. We aimed to investigate the role of JAZF1 in cardiac fibrosis. Methods: A rat cardiac fibrosis model was established by administering isoproterenol subcutaneously for 14 days (5 mg/kg/day); an equal volume of saline was administered to the control group. Cardiac fibroblasts (CFs) were treated with TGF-β1 for 48 h to mimic cardiac fibrosis in vitro. Results: JAZF1 expression at the protein and mRNA levels was enhanced in CFs and cardiac fibrosis tissues. JAZF1 downregulation suppressed CFs’ proliferation and migration. Western blotting showed that the PI3K/Akt signaling pathway was significantly decreased after JAZF1 knockdown. Further experiments revealed that SOX11 is an important transcription factor whose overexpression and downregulation enhanced and suppressed JAZF1 levels, respectively. Luciferase analysis showed that SOX11 interacted with the JAZF1 promoter. Moreover, SOX11 promoted cardiac fibrosis by regulating JAZF1 expression. Conclusions: JAZF1 was enhanced in cardiac fibrosis tissue and TGF-β-treated CFs. JAZF1 knockdown decreased CFs’ migration and proliferation, possibly remediated by SOX11 with activation of PI3k/Akt signaling pathways.
Background: Mild alanine transaminase (ALT) elevation is common in older patients with acute myocardial infarction (AMI), but its prognostic value and implications for statin therapy remain unclear. Methods: This retrospective cohort study included 321 AMI patients aged ≥ 75 years admitted from 2014 to 2019 at Guangdong Provincial People’s Hospital. Mild ALT elevation was defined as ALT between the upper limit of normal (ULN) and 3 × ULN, and significant elevation as ALT > 3 × ULN. Patients were grouped by admission ALT into normal (N, n = 201), mildly elevated (ME, n = 104), and significantly elevated (SE, n = 16). Logistic regression analyses in SPSS 26.0 and R 3.4.3 assessed the association between ALT levels and in‐hospital mortality, adjusting for cardiac function, infarct size, renal function, and treatment factors. Results: Among survivors with elevated ALT, 87.4% achieved normalization before discharge. Statin intolerance was identified in 58 patients (18.9%) at admission and persisted in 6.7% at discharge. The ALT‐ME group had significantly higher statin intolerance (36.5% vs. 2.0%, p < 0.001) and higher in‐hospital mortality (18.3% vs. 6.0%, p = 0.001) compared with the ALT‐N group. Logistic regression analysis demonstrated that ALT elevation was independently associated with higher in‐hospital mortality (per 10 U/L ALT elevation, odds ratio 1.164, p = 0.010). Conclusion: In older patients with AMI, mild elevation in ALT levels upon admission is associated with worse in‐hospital outcomes, and statin intolerance is common and mostly reversible. Short‐term substitutes for statins should be considered in these patients.